Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28968669.
- Also identified by DOI 10.1093/infdis/jix398 and PMC identifier 5853262.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As treatment options coalesce around a smaller number of antiretroviral drugs (ARVs), data are emerging on the drug resistance mutations (DRMs) selected by the most widely used ARVs and on the impact of these DRMs on ARV susceptibility and virological response to first- and later-line treatment regimens. Recent studies have described the DRMs that emerge in patients receiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir, and the integrase inhibitors raltegravir and elvitegravir. Several small studies have described DRMs that emerge in patients receiving dolutegravir.
Medical subject headings
- Anti-HIV Agents
- HIV-1
- Mutation